ClinicalTrials.gg
CompletedNCT03039192Aspire IUpdated Apr 29, 2025Results posted

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

A Phase 3 interventional study of Esketamine and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 56 sites in 11 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
5th of 17
226 · median 147
Started
2017
with 2 others
Phase 3
7 of 17
2 open now
Registered
4th of 17
by date
Lead sponsor
7 of 17
Janssen Research & Development, LLC

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 4th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

Read the detailed description

This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled (an inactive substance which contains no drug) that is compared in a clinical trial with a drug to test if the drug has a real effect), multicenter (when more than one hospital or study team work on a medical research study) study. Study will enroll participants with suicidal ideation who are assessed to be at imminent risk for suicide. The study will consist of a screening evaluation performed within 48 hours prior to the Day 1 intranasal dose immediately followed by a 25-day double-blind treatment phase (Day 1 to 25), and a 65 day follow-up phase (Day 26 to Day 90). The total study duration for each subject will be approximately 13 weeks. Participants' safety will be evaluated throughout the study. If you or a loved one are having thoughts of suicide, please seek immediate medical help. Go to the emergency room or call the National Suicide Prevention Lifeline at 1-800-273-8255.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must meet (5th edition) (DSM-5) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI)
  • In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to participant's imminent risk of suicide
  • Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?] and Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI. Note: the response to B3 must refer to the present, whereas the response to B10 may reflect the past 24 hours. If the screening period is longer than 24 hours, assessment of B3 and B10 of MINI must be repeated prior to randomization to confirm eligibility
  • Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (>) 28 predose on Day 1
  • As part of standard of care treatment, participant agrees to be hospitalized voluntarily for a recommended period of 5 days after randomization (may be shorter or longer if clinically warranted in the investigator's opinion) and take prescribed non- antidepressant therapy(ies) for at least the duration of the double-blind treatment phase (Day 25)
  • Participant is comfortable with self-administration of intranasal medication and able to follow instructions provided

Exclusion criteria

Exclusion Criteria:

  • Participant has a current diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder
  • Participant currently meets DSM-5 criteria for borderline personality disorder. Participant not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded
  • Participant has a current clinical diagnosis of autism, dementia, or intellectual disability
  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features
  • Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, (except for nicotine or caffeine), within the 6 months before screening. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Esketamine + Standard of care

    Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.

    Drug: Esketamine · Other: Standard of Care

  • Placebo comparator
    Placebo + Standard of care

    Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.

    Other: Placebo · Other: Standard of Care

Interventions

  • Intranasal esketamine solution 84 milligram (mg)

  • OtherPlacebo

    Intranasal Placebo solution

  • OtherStandard of Care

    The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF] Data) During Double-blind Phase

    MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression of Severity of Suicidality- Revised (CGI-SS-R) Score at 24 Hours After the First Dose (Day 2) (LOCF Data) During Double-blind Phase

    CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality).

    Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

  2. Number of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase

    Participants who had a MADRS total score of \<=12 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement.

    Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25 (predose and 4 hours postdose)

  3. Change From Baseline in Montgomery Asberg Depression Rating Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement.

    Time frame: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)

  4. Change From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

    CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25

  5. Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase

    CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. A participant was considered to achieve resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal).

    Time frame: Days 1, 2, 4, 8, 11, 15, 18, 22 and 25

  6. Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

    The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25

  7. Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 During Double-blind Phase

    BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.

    Time frame: Baseline, Days 8 and 25

  8. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Health Status Index

    EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health). Positive change in score indicates improvement.

    Time frame: Baseline and Days 2, 11 and 25

  9. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: EQ-Visual Analogue Scale (EQ-VAS)

    EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score from 0 (worst health) to 100 (best health), positive change in score indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  10. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Sum Score

    EQ-5D-5L measures health outcome. It consists of EQ-5D-5L system and EQ-VAS. EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, and Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health), a lower score indicates worse health. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Sum score ranges from 0-100. Higher score indicates a more severe problem. Negative change in score indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  11. Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 During Double-blind Phase

    The QLDS is a disease specific patient-reported outcome designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the moment", contains 34-items with "true"/"not true" response options and takes approximately 5-10 minutes to complete. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

    Time frame: Baseline and Days 2, 11 and 25

  12. Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score at Days 15 and 25 During Double-blind Phase

    The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.

    Time frame: Days 15 and 25

  13. Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Patient-reported FoST) Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

    SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). SIBAT Module 5 (My Risk) Question 3 (Patient-reported FoST) total score ranges from 0 to 4; a higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline, Days 1, 2, 4, 8, 11, 15, 18, 22 and 25

  14. Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 - Clinician-rated FoST Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

    SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking (FoST) that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25

  15. Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.

    Time frame: Up to Day 25

  16. Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase

    Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin(low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine(High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).

    Time frame: Up to Day 25

  17. Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase

    Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.

    Time frame: At Day 25

  18. Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase

    Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.

    Time frame: Up to Day 25

  19. Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase

    Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.

    Time frame: Up to Day 25

  20. Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase

    Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.

    Time frame: Up to Day 25

  21. Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase

    MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.

    Time frame: Up to Day 25

  22. Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase

    The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.

    Time frame: Days 1, 4, 8, 11, 15, 18, 22 and 25

07

Results

Posted Oct 29, 2020
Limitations and caveats
Esketamine's known characteristic effects such as dissociative symptoms, sedation, and elevation of blood pressure may have impact on blinding, to minimize this bias, protocol specified that different raters perform efficacy and safety assessments.

Participant flow

Participant flow — Overall Study
MilestonePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Started112114
Treated112113
Completed8084
Not completed3230
Withdrew: Lost to follow-up44
Withdrew: Adverse event, serious fatal01
Withdrew: Adverse event, non-fatal02
Withdrew: Withdrawal by subject69
Withdrew: Discontinued from treatment phase1912
Withdrew: Other32

Outcome measures

PrimaryChange From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF] Data) During Double-blind Phase

MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF] Data) During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF] Data) During Double-blind Phase-12.8 ± 10.73-16.4 ± 11.95
Statistical analysis
  • Placebo Plus SOC Antidepressant Treatment vs Esketamine 84 mg Plus SOC Antidepressant Treatment · ANCOVA · p = 0.006 · Difference of least square means: -3.8 · 95% CI -6.56 to -1.09
SecondaryChange From Baseline in Clinical Global Impression of Severity of Suicidality- Revised (CGI-SS-R) Score at 24 Hours After the First Dose (Day 2) (LOCF Data) During Double-blind Phase

CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality).

Time frame:
Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression of Severity of Suicidality- Revised (CGI-SS-R) Score at 24 Hours After the First Dose (Day 2) (LOCF Data) During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change From Baseline in Clinical Global Impression of Severity of Suicidality- Revised (CGI-SS-R) Score at 24 Hours After the First Dose (Day 2) (LOCF Data) During Double-blind Phase-1.0 (-5 to 1)-1.0 (-6 to 2)
SecondaryNumber of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase

Participants who had a MADRS total score of \<=12 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement.

Time frame:
Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25 (predose and 4 hours postdose)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Day 1 (4 Hours postdose)912
Day 21021
Day 41328
Day 82330
Day 112633
Day 152938
Day 183042
Day 222541
Day 25 (Predose)3846
Day 25 (4 hours postdose)4260
SecondaryChange From Baseline in Montgomery Asberg Depression Rating Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition and a negative change in score indicates improvement.

Time frame:
Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery Asberg Depression Rating Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 1-10.9 ± 9.69-13.5 ± 10.89
Change at Day 2-12.9 ± 10.72-16.4 ± 11.95
Change at Day 4-14.5 ± 11.39-19.1 ± 12.29
Change at Day 8-17.4 ± 12.59-19.7 ± 12.91
Change at Day 11-19.0 ± 12.08-21.8 ± 12.20
Change at Day 15-20.4 ± 12.19-22.3 ± 11.70
Change at Day 18-21.4 ± 12.00-23.9 ± 11.77
Change at Day 22-21.6 ± 12.32-24.0 ± 12.38
Change at Day 25: predose-23.0 ± 12.41-24.8 ± 13.63
Change at Day 25 (4 hours postdose)-25.8 ± 10.94-29.5 ± 10.89
SecondaryChange From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 10.0 (-5 to 1)-1.0 (-6 to 1)
Change at Day 2-1.0 (-5 to 1)-1.0 (-6 to 2)
Change at Day 4-1.0 (-5 to 1)-2.0 (-6 to 2)
Change at Day 8-2.0 (-5 to 0)-2.0 (-6 to 1)
Change at Day 11-2.0 (-5 to 1)-3.0 (-6 to 1)
Change at Day 15-2.0 (-5 to 0)-3.0 (-5 to 0)
Change at Day 18-2.5 (-5 to 0)-3.0 (-6 to 1)
Change at Day 22-3.0 (-5 to 1)-3.0 (-6 to 1)
Change at Day 25-3.0 (-5 to 1)-3.0 (-6 to 1)
SecondaryNumber of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase

CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition. Negative change in score indicates improvement. A participant was considered to achieve resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal).

Time frame:
Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Day 12537
Day 23942
Day 44549
Day 84853
Day 114660
Day 155268
Day 185568
Day 226270
Day 255771
SecondaryChange From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 10.0 (-4 to 2)-1.0 (-5 to 3)
Change at Day 2-1.0 (-5 to 2)-1.0 (-5 to 2)
Change at Day 4-1.0 (-5 to 2)-2.0 (-5 to 2)
Change at Day 8-2.0 (-5 to 2)-2.0 (-6 to 1)
Change at Day 11-2.0 (-5 to 1)-2.0 (-6 to 1)
Change at Day 15-2.0 (-5 to 2)-3.0 (-5 to 2)
Change at Day 18-3.0 (-5 to 1)-3.0 (-5 to 2)
Change at Day 22-3.0 (-5 to 1)-3.0 (-6 to 1)
Change at Day 25-3.0 (-5 to 2)-3.0 (-6 to 1)
SecondaryChange From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 During Double-blind Phase

BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.

Time frame:
Baseline, Days 8 and 25
Reported as:
Mean · units on a scale
Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 8-4.4 ± 6.03-5.3 ± 6.06
Change at Day 25-6.6 ± 6.63-6.9 ± 6.92
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Health Status Index

EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health). Positive change in score indicates improvement.

Time frame:
Baseline and Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Health Status Index
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 20.096 ± 0.17850.156 ± 0.1944
Change at Day 110.169 ± 0.21390.206 ± 0.2043
Change at Day 250.189 ± 0.23360.227 ± 0.2078
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: EQ-Visual Analogue Scale (EQ-VAS)

EQ-5D-5L measures health outcome. It consists of EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score from 0 (worst health) to 100 (best health), positive change in score indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: EQ-Visual Analogue Scale (EQ-VAS)
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 27.8 ± 17.3213.5 ± 20.78
Change at Day 1116.3 ± 22.2717.9 ± 24.55
Change at Day 2520.0 ± 23.4921.4 ± 26.71
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Sum Score

EQ-5D-5L measures health outcome. It consists of EQ-5D-5L system and EQ-VAS. EQ-5D-5L system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimensions is divided into 5 levels of perceived problems (Level 1-no problem, Level 2-slight problems, Level 3-moderate problems, Level 4-severe problems, and Level 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a health status index (HSI). Health Status Index ranges from 0.148 - 0.949, anchored at 0 (dead) and 1 (full health), a lower score indicates worse health. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Sum score ranges from 0-100. Higher score indicates a more severe problem. Negative change in score indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) at Days 2, 11 and 25 During Double-blind Phase: Sum Score
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 2-6.1 ± 12.28-11.2 ± 14.87
Change at Day 11-12.3 ± 16.23-15.2 ± 15.75
Change at Day 25-13.4 ± 18.05-16.8 ± 16.30
SecondaryChange From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 During Double-blind Phase

The QLDS is a disease specific patient-reported outcome designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the moment", contains 34-items with "true"/"not true" response options and takes approximately 5-10 minutes to complete. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

Time frame:
Baseline and Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 2-2.5 ± 4.55-3.1 ± 5.14
Change at Day 11-4.4 ± 5.93-5.6 ± 5.92
Change at Day 25-5.6 ± 5.99-6.8 ± 5.97
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score at Days 15 and 25 During Double-blind Phase

The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.

Time frame:
Days 15 and 25
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score at Days 15 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Effectiveness: Day 1551.7 ± 25.7463.5 ± 23.72
Effectiveness: Day 2557.6 ± 24.6665.8 ± 25.23
Convenience: Day 1570.9 ± 19.5770.5 ± 20.75
Convenience: Day 2574.0 ± 19.3871.3 ± 19.69
Global Satisfaction: Day 1552.2 ± 28.5764.5 ± 24.62
Global Satisfaction: Day 2555.7 ± 27.4468.5 ± 25.51
SecondaryChange From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Patient-reported FoST) Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time). SIBAT Module 5 (My Risk) Question 3 (Patient-reported FoST) total score ranges from 0 to 4; a higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline, Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Patient-reported FoST) Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 10.0 (-4 to 2)0.0 (-3 to 1)
Change at Day 2-1.0 (-4 to 1)-1.0 (-4 to 2)
Change at Day 4-1.0 (-4 to 2)-1.0 (-4 to 1)
Change at Day 8-1.0 (-4 to 1)-1.0 (-4 to 1)
Change at Day 11-1.0 (-4 to 1)-1.5 (-4 to 1)
Change at Day 15-1.0 (-4 to 1)-2.0 (-4 to 1)
Change at Day 18-2.0 (-4 to 1)-2.0 (-4 to 1)
Change at Day 22-2.0 (-4 to 2)-2.0 (-4 to 1)
Change at Day 25-2.0 (-4 to 1)-2.0 (-4 to 1)
SecondaryChange From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 - Clinician-rated FoST Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase

SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking (FoST) that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline and Days 1, 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 - Clinician-rated FoST Total Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25 During Double-blind Phase
units on a scalePlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Change at Day 1-1.0 (-5 to 2)-1.0 (-5 to 1)
Change at Day 2-1.0 (-5 to 1)-1.0 (-5 to 1)
Change at Day 4-1.0 (-5 to 1)-2.0 (-5 to 2)
Change at Day 8-2.0 (-5 to 2)-2.0 (-5 to 1)
Change at Day 11-2.0 (-5 to 2)-2.0 (-5 to 2)
Change at Day 15-2.0 (-5 to 0)-2.0 (-5 to 1)
Change at Day 18-2.0 (-5 to 1)-2.0 (-5 to 1)
Change at Day 22-2.0 (-5 to 1)-2.0 (-5 to 1)
Change at Day 25-2.0 (-5 to 1)-3.0 (-5 to 1)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase83100
SecondaryNumber of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase

Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin(low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine(High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
ALT>3*ULN11
ALT: Abnormal High11
Albumin: Abnormal High00
Albumin: Abnormal Low00
Alkaline phosphatase (ALP): Abnormal High00
AST: AST>3*ULN00
AST: Abnormal High00
Bicarbonate: Abnormal High00
Bicarbonate: Abnormal Low00
Bilirubin: Abnormal High00
Calcium: Abnormal High00
Calcium: Abnormal Low00
Chloride: Abnormal High00
Chloride: Abnormal Low00
Creatine Kinase (CK): Abnormal High01
Creatinine: Abnormal High00
GGT: Abnormal High00
Glucose: Abnormal High00
Glucose: Abnormal Low00
ALT>3*ULN or AST>3*ULN and BILI>2*ULN00
Lactate Dehydrogenase(LD): Abnormal High00
Phosphate: Abnormal High00
Phosphate: Abnormal Low12
Potassium: Abnormal High00
Potassium: Abnormal Low00
Protein: Abnormal Low00
Sodium: Abnormal High00
Sodium: Abnormal Low00
Urate: Abnormal High00
Urate: Abnormal Low00
Basophils: Abnormal High00
Eosinophils: Abnormal High00
Erythrocytes: Abnormal High11
Erythrocytes: Abnormal Low00
Hematocrit: Abnormal High00
Hematocrit: Abnormal Low00
Hemoglobin(Hb): Abnormal High00
Hemoglobin: Abnormal Low00
Leukocytes: Abnormal High00
Leukocytes: Abnormal Low10
Lymphocytes: Abnormal High00
Lymphocytes: Abnormal Low00
Monocytes: Abnormal High00
Neutrophils: Abnormal High00
Neutrophils: Abnormal Low00
Platelets: Abnormal High00
Platelets: Abnormal Low02
Urine pH: Abnormal High00
SecondaryNumber of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase

Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.

Time frame:
At Day 25
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Epistaxis: Mild01
Epistaxis: Moderate00
Epistaxis: Severe00
Nasal Crusts: Mild10
Nasal Crusts: Moderate00
Nasal Crusts: Severe00
Nasal Discharge: Mild03
Nasal Discharge: Moderate00
Nasal Discharge: Severe00
Nasal Erythema: Mild43
Nasal Erythema: Moderate00
Nasal Erythema: Severe00
SecondaryNumber of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase

Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Heart Rate <= 50 bpm82
Heart Rate >= 100 bpm45
PR Duration >= 210 msec35
QRS Duration <= 50 msec00
QRS Duration >= 120 msec00
QT Duration <= 200 msec00
QT Duration >= 500 msec00
SecondaryNumber of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase

Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase21
SecondaryNumber of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase

Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Pulse rate (bpm): Decrease of >=15 to <=5023
Pulse rate (bpm): Increase of >=15 to >=100613
SBP (mmHg): Decrease of >=20 to <=9040
SBP (mmHg): Increase of >=20 to >=18002
DBP (mmHg): Decrease of >=15 to <=5040
DBP (mmHg): Increase of >=15 to >=105111
SecondaryNumber of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase

MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Score <=2: Yes03
Score <=3: Yes113
Score <=4: Yes2043
SecondaryNumber of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase

The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.

Time frame:
Days 1, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Count of participants · Participants
Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase
ParticipantsPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Day 13495
Day 42384
Day 82981
Day 111977
Day 151769
Day 181970
Day 221670
Day 251472

Adverse events

Collected over Up to Day 25. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus SOC Antidepressant Treatment0/112 (0%)6/112 (5.4%)66/112 (58.9%)
Esketamine 84 mg Plus SOC Antidepressant Treatment0/113 (0%)4/113 (3.5%)91/113 (80.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
Suicidal IdeationPsychiatric disorders2/1120/113
Depression SuicidalPsychiatric disorders1/1122/113
HypertransaminasaemiaHepatobiliary disorders1/1120/113
AggressionPsychiatric disorders1/1120/113
DepressionPsychiatric disorders1/1121/113
Suicide AttemptPsychiatric disorders1/1121/113
Diabetic KetoacidosisMetabolism and nutrition disorders0/1121/113
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant Treatment
DizzinessNervous system disorders10/11240/113
DissociationPsychiatric disorders4/11233/113
NauseaGastrointestinal disorders15/11223/113
HeadacheNervous system disorders20/11221/113
SomnolenceNervous system disorders11/11221/113
Blood Pressure IncreasedInvestigations6/11219/113
DysgeusiaNervous system disorders11/11216/113
ConstipationGastrointestinal disorders5/11215/113
AnxietyPsychiatric disorders10/1126/113
Vision BlurredEye disorders5/11210/113

Baseline characteristics

Safety analysis set included all randomized participants who received at least 1 dose of study agent in the double-blind treatment phase.

Age, Continuous
Age, Continuous(years)Placebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant TreatmentTotal
Mean37.9 ± 12.5440.8 ± 13.1139.3 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant TreatmentTotal
Female7366139
Male394786
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant TreatmentTotal
Asian282856
Black or African American7512
More than one race112
Native Hawaiian or Other Pacific Islander011
Other213
White7477151
Region of Enrollment
Region of Enrollment(Participants)Placebo Plus SOC Antidepressant TreatmentEsketamine 84 mg Plus SOC Antidepressant TreatmentTotal
BULGARIA10919
ESTONIA134
GERMANY10818
HUNGARY8715
MALAYSIA9716
SOUTH AFRICA8715
SOUTH KOREA101020
SPAIN202444
TAIWAN8917
UNITED STATES282957
08

Study locations

56 sites
  • UAB Department of Psychiatry and Behavioral Neurobiology
    Birmingham, Alabama 35294, United States
  • Metropolitan Neuro Behavioral Institute
    Chandler, Arizona 85226, United States
  • Collaborative NeuroScience Network
    Garden Grove, California 92845, United States
  • Yale University
    New Haven, Connecticut 06511, United States
  • Rush University
    Chicago, Illinois 60612, United States
  • Alexian Behavioral Health Hospital
    Hoffman Estates, Illinois 60169, United States
  • University of Louisville Department of Psychiatry
    Louisville, Kentucky 40202, United States
  • LSU Health Sciences Center New Orleans
    New Orleans, Louisiana 70115, United States
  • Louisiana Clinical Research
    Shreveport, Louisiana 71101, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • State University of New York
    Buffalo, New York 14215, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Clinical Trials of America
    Hickory, North Carolina 28601, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Mental Health Center Prof. Dr. Ivan Temkov
    Bourgas, 8001, Bulgaria
  • Regional Psychiatric Dispansery
    Bulgaria, 7003, Bulgaria
  • State Psychiatric Hospital - Lovech
    Lovech, 5500, Bulgaria
  • UMHAT 'Sveti Georgi'-Plovdiv
    Plovdiv, 4002, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment Sofia
    Sofia, 1606, Bulgaria
  • North Estonian Medical Centre Foundation
    Tallinn, 10614, Estonia
  • Tartu University Hospital
    Tartu, 50417, Estonia
  • Vivantes Humboldt Klinikum
    Berlin, 13509, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt Am Main, 60528, Germany
  • Klinik für Psychiatrie und Psychotherapie
    Freiburg, 79104, Germany
  • Eszak Kozep budai Centrum Uj Szent Janos Korhaz es Szakrendelo Budai Csaladkozpontu
    Budapest, 1125, Hungary
  • Semmelweis Egyetem Kútvölgyi Klinikai Tömb
    Budapest, 1125, Hungary
  • Nyiro Gyula Korhaz
    Budapest, 1135, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, H-9024, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7623, Hungary
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Korea University Ansan Hospital
    Gyeonggi-do, 15355, Korea, Republic of
  • Kyung Hee University Medical Center
    Seoul, 02447, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 3080, Korea, Republic of
  • University Kebangsaan Malaysia Medical Centre
    Cheras, 56000, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Hospital Tuanku Jaafar
    Seremban, 70300, Malaysia
  • Fakultna nemocnica s poliklinikou v Ziline
    Zilina, 012 07, Slovakia
  • Flexivest 14 Research
    Cape Town, 7550, South Africa
  • Juan Schrönen - Western Cape South Africa
    Welgemoed, 7530, South Africa
  • Hosp. Univ. Fundacion Alcorcon
    Alcorcón, 28922, Spain
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Inst. Internac. Neurociencias Aplicadas
    Barcelona, 8006, Spain
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Benito Menni Comp. Asist. Salut Mental
    Sant Boi de Llobregat, 08830, Spain
  • Tri-Service Genaral Hospital
    Neihu District, 114, Taiwan
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 40201, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Rozjabek H, Li N, Hartmann H, Fu DJ, Canuso C, Jamieson C. Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray. J Patient Rep Outcomes. 2022 Jul 10;6(1):74. doi: 10.1186/s41687-022-00453-y. PubMed 35816217 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
  • Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, Nash AI, Lopena TJ, Fu DJ. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):516-524. doi: 10.1097/JCP.0000000000001465. PubMed 34412104 ↗
  • Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry. 2020 May 12;81(3):19m13191. doi: 10.4088/JCP.19m13191. PubMed 32412700 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Dec 2018, 18 months.

Results were first posted in Oct 2020, 1 year 10 months after primary completion. A results delay was requested in Dec 2019.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 18 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 1, 2017
StartActual
Jun 9, 2017
Primary completionActual
Dec 18, 2018
CompletionActual
Dec 18, 2018
Results delay requested
Dec 16, 2019
Results first posted
Oct 29, 2020
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03039192
Responsible party
Sponsor
First posted
Feb 1, 2017
Start date
Jun 9, 2017
Primary completion
Dec 18, 2018
Completion
Dec 18, 2018
Results posted
Oct 29, 2020
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion